Views & Analysis Tracking studies: moving with the times Awareness, Trial, and Usage tracking can be enhanced if technology updates it in real time.
News Otsuka eyes early filing of IgAN drug after phase 3 readout Otsuka is hoping to file for approval of its anti-APRIL antibody sibeprenlimab as a treatment for kidney disorder IgA nephropathy (IgAN) after the drug hit the target in a phase 3 trial.
Sales & Marketing Sponsored Global reach, personal touch: Mastering customer engagement ... In today's interconnected pharma market, the ability to scale engagement across borders is essential for survival and growth.